Liminatus Pharma transfers to Nasdaq Capital Market, gets bid-price extension
Liminatus Pharma (LIMN) announces its transfer to the Nasdaq Capital Market and an extension aimed at regaining compliance with the Nasdaq minimum bid price requirement.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.